(1.03%) 5 180.74 points
(0.46%) 38 852 points
(1.19%) 16 349 points
(0.38%) $78.78
(-1.50%) $2.16
(0.02%) $2 331.70
(-0.18%) $27.57
(0.70%) $971.70
(0.05%) $0.929
(0.21%) $10.85
(0.05%) $0.796
(-0.02%) $91.33
0.42% CHF 72.50
Live Chart Being Loaded With Signals
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide...
Stats | |
---|---|
Dzisiejszy wolumen | 14 718.00 |
Średni wolumen | 18 555.00 |
Kapitalizacja rynkowa | 1.17B |
EPS | CHF0 ( 2024-03-20 ) |
Następna data zysków | ( CHF0 ) 2024-07-24 |
Last Dividend | CHF0 ( N/A ) |
Next Dividend | CHF0 ( N/A ) |
P/E | 111.54 |
ATR14 | CHF0.145 (0.20%) |
Wolumen Korelacja
Cosmo Pharmaceuticals NV Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Cosmo Pharmaceuticals NV Korelacja - Waluta/Towar
Cosmo Pharmaceuticals NV Finanse
Annual | 2023 |
Przychody: | CHF96.72M |
Zysk brutto: | CHF57.38M (59.33 %) |
EPS: | CHF0.0710 |
FY | 2023 |
Przychody: | CHF96.72M |
Zysk brutto: | CHF57.38M (59.33 %) |
EPS: | CHF0.0710 |
FY | 2023 |
Przychody: | CHF0 |
Zysk brutto: | CHF0 (0.00 %) |
EPS: | CHF0 |
FY | 2022 |
Przychody: | CHF102.09M |
Zysk brutto: | CHF83.33M (81.62 %) |
EPS: | CHF1.050 |
Financial Reports:
No articles found.
Cosmo Pharmaceuticals NV
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej